Horizon Therapeutics plc Announces Phase 2 Trial Evaluating Dazodalibep for the Treatment of Sjögren's Syndrome Meets Primary Endpoint in the Second Study Population; Only Phase 2 Trial to Meet Primary Endpoint in Both Patient Populations

Trial also met primary endpoint in first study population as announced September 2022 - The Company plans to work with the FDA to design a Phase 3 program to begin in 2023, ahead of expectations - Horizon

Related Keywords

Ireland ,Tina Ventura ,Geoff Curtis ,Erin Linnihan ,Ray Gordon ,Instagram ,European Alliance Of Associations ,Linkedin ,Twitter ,Facebook ,Nasdaq ,Corporate Affairs ,European Alliance ,Syndrome Patient Reported Index ,Syndrome Trial ,Ocular Surface Disease Index ,After Total Knee ,Vice President ,Chief Investor Relations Officer ,Investor Relations ,Corporate Affairs Chief Communications Officer ,Horizon ,Herapeutics ,Nnounces ,Hase ,Trial ,Valuating ,Azodalibep ,Treatment ,J 246 Gren ,Yndrome ,Meets ,Primary ,Ndpoint ,Second ,Study ,Population ,Only ,Feet ,Moth ,Patient ,Populations ,